Welcome to our dedicated page for Predictive Oncology news (Ticker: POAI), a resource for investors and traders seeking the latest updates and insights on Predictive Oncology stock.
Predictive Oncology Inc. news covered the company's shift from AI-driven oncology drug discovery into digital asset treasury and AI compute infrastructure activities. Recurring updates included financial results, Nasdaq listing compliance, a reverse stock split, private placements, governance changes, and the Aethir (ATH) token strategy tied to a Strategic Compute Reserve.
The company's oncology-related updates centered on its artificial intelligence and machine-learning platform, tumor sample biorepository, CLIA laboratory capabilities, and collaborations for drug repurposing and cancer therapy response prediction.
Predictive Oncology (NASDAQ: POAI) has announced significant progress in AI-enabled cancer drug discovery, leveraging its extensive biobank of over 150,000 live cell tumor samples across 137 cancer indications. The company successfully developed predictive tumor response models for 21 previously untested molecules from the University of Michigan, targeting common cancers including breast, colon, and ovarian cancers.
This announcement coincides with Regeneron's $256 million acquisition of 23andMe, highlighting the industry's shift toward data-driven drug discovery. The company's proprietary active machine learning platform enables in silico drug response testing before in vitro confirmation, significantly accelerating development timelines and improving the Probability of Technical Success in drug development.
Predictive Oncology (NASDAQ: POAI) has developed a novel approach to repurpose abandoned oncology drugs using active machine learning and their biobank of patient-derived tumor cells. The company successfully identified three promising compounds in less than 12 weeks:
1. Afuresertib (Akt inhibitor): Showed strong results in ovarian and colon tumors
2. Alisertib (Aurora A Inhibitor): Outperformed standard care drugs in colon and breast cancer
3. Entinostat (HDAC1/3 inhibitor): Demonstrated strong response in colon samples
The screening method efficiently evaluated these compounds against tumor indications that were previously unexplored. Notably, Alisertib and Entinostat outperformed Oxaliplatin in colon tumor treatment, while Alisertib also showed superior results compared to Ribociclib in breast cancer treatment.
Predictive Oncology (POAI) reported its financial results for Q4 and full-year 2024, posting a $10.8 million loss from continuing operations on revenue of $1.6 million. The company is progressing toward a definitive merger agreement with Renovaro Inc, having received the first tranche of financing to integrate AI/ML platforms and expand operations.
Key developments include the sale of Skyline Medical subsidiary to DeRoyal Industries, partnership with Tecan Group for high-throughput drug screening, and planned European launch of ChemoFx® drug response assay. The company raised over $3.0 million in Q1 2025 through various financing activities.
Financial highlights: Cash position decreased to $734,673 from $8.7 million year-over-year, with stockholder's deficit of $(202,610). Revenue remained relatively flat at $1.62 million compared to $1.63 million in 2023. Operating expenses decreased across all categories, with general and administrative expenses down by $961,025 to $7.42 million.
Predictive Oncology (NASDAQ: POAI) has successfully developed predictive models from 21 unique compounds sourced from the Natural Products Discovery Core (NPDC) at the University of Michigan Life Sciences Institute. The company's AI-driven platform evaluated these compounds for tumor response across breast, colon, and ovary cancer types.
Key findings include:
- Three compounds showed stronger tumor response than the benchmark drug Doxorubicin across all tested tumor types
- A fourth compound demonstrated strong response in ovary and colon models
- Three additional compounds showed significant 'hit responses' across all tumor types
- The ML model achieved 73% prediction coverage while only requiring 7% of possible wet lab experiments, potentially saving up to two years of laboratory testing
The NPDC library, one of the largest pharmaceutically viable natural products collections in the United States, contains specimens from global biodiverse hotspots. Natural products have historically contributed to at least half of approved small-molecule drugs in the past three decades.
Predictive Oncology (NASDAQ: POAI) has completed the sale of its Skyline Medical subsidiary's assets to DeRoyal Industries, a global medical products manufacturer. The transaction involves the STREAMWAY® System, an FDA-cleared direct-to-drain wall suction waste fluid management technology.
The sale aligns with POAI's strategic focus on AI-driven drug discovery and comes ahead of its planned merger with Renovaro Biosciences. The company had implemented a restructuring plan for Skyline Medical in late 2023, successfully returning the unit to profitability by the end of 2024.
DeRoyal Industries will integrate the STREAMWAY® System into its product portfolio under its own brand, maintaining service continuity for existing customers while expanding market reach. The system provides healthcare professionals with an automated solution for managing potentially hazardous fluids during medical procedures, designed to reduce manual handling and eliminate spillage risks.
Predictive Oncology (NASDAQ: POAI) has received the first tranche of financing from Renovaro Biosciences (NASDAQ: RENB) to begin integrating AI/ML platforms, laboratory capabilities, and business development efforts across Europe and the US. The companies are moving towards finalizing a definitive merger agreement, expected within weeks.
The merger aims to combine Predictive's AI-driven drug discovery platform, which includes a biobank of over 150,000 patient tumor samples and 200,000 pathology slides, with Renovaro's multi-disciplinary AI and multi-omic expertise. This integration has been enhanced by Renovaro's recent acquisition of BioSymetrics, which expands opportunities in biomarker and drug discovery, along with diagnostic applications in oncology.
The combined entity will focus on improving cancer patient outcomes through earlier diagnosis, biomarker discovery, and targeted therapies. The merger is expected to enhance shareholder value and strengthen the company's position in capital markets.